RecruitingPhase 3NCT05555589

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Studying Neurotrophic keratopathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: ReGenTree, LLC
Intervention: RGN-259(drug)
Enrollment: 70 target
Eligibility: 18 years · All sexes
Timeline: 2023 – 2026

Study locations (30)

Harvard Eye Associates, Laguna Hills, California, United States
Loma Linda University Eye Institute, Loma Linda, California, United States
Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
Advance Vision Research Institute, Longmont, Colorado, United States
Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons, Danbury, Connecticut, United States
Nature Coast Clinical Research, Crystal River, Florida, United States
University of Miami - Bascom Palmer Eye Institute, Miami, Miami, Florida, United States
University of South Florida, Ophthalmolgoy, Tampa, Florida, United States
Thomas Eye Group, P.C., Sandy Springs, Georgia, United States
Northwestern, Chicago, Illinois, United States
Midwest Cornea Associates, LLC., Carmel, Indiana, United States
Huffman & Huffman, PSC, Lexington, Kentucky, United States
Midwest Vision Research Foundation, Chesterfield, Missouri, United States
Washington University Eye Center, St Louis, Missouri, United States
Metropolitan Eye Research and Surgery Institute, Palisades Park, New Jersey, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05555589 on ClinicalTrials.gov

Other trials for Neurotrophic keratopathy

Additional recruiting or active studies for the same condition.

See all trials for Neurotrophic keratopathy →

← Back to all trials